Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CLVS

Clovis Oncology (CLVS) Stock Price, News & Analysis

Clovis Oncology logo

About Clovis Oncology Stock (NASDAQ:CLVS)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.08
$1.09
52-Week Range
N/A
Volume
1.16 million shs
Average Volume
8.88 million shs
Market Capitalization
$11.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CLVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clovis Oncology and its competitors with MarketBeat's FREE daily newsletter.

CLVS Stock News Headlines

Clovis Chamber names new Retail Rockstar
Elon’s NEXT Big IPO?
Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it takes for the entire thing to burn right up. It’s a NEW internet service poised to disrupt the entire $3.2 trillion telecom industry. But you may only have this chance if you act before December 31st, 2025.
Cancer Horoscope
See More Headlines

CLVS Stock Analysis - Frequently Asked Questions

Clovis Oncology (NASDAQ:CLVS) announced its earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $0.08. The biopharmaceutical company had revenue of $37.92 million for the quarter, compared to analysts' expectations of $38.73 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Clovis Oncology investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Bristol Myers Squibb (BMY), NIO (NIO) and Micron Technology (MU).

Company Calendar

Last Earnings
11/03/2021
Today
7/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CLVS
Employees
N/A
Year Founded
2009

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$264.52 million
Net Margins
-189.37%
Pretax Margin
-189.68%

Debt

Sales & Book Value

Annual Sales
$148.76 million
Price / Cash Flow
N/A
Book Value
($2.15) per share
Price / Book
N/A

Miscellaneous

Free Float
138,577,000
Market Cap
$11.60 million
Optionable
Optionable
Beta
0.24

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:CLVS) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners